Production (Stage)
COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2025 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -54.85% | 1,600.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -54.85% | 1,600.00% | |||
| Cost of Revenue | -16.97% | 1,996.36% | |||
| Gross Profit | -78.38% | 1,269.70% | |||
| SG&A Expenses | 6.55% | -193.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.18% | -103.07% | |||
| Operating Income | -0.19% | 135.29% | |||
| Income Before Tax | 35.30% | 67.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.70% | 75.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.70% | 75.14% | |||
| EBIT | -0.19% | 135.29% | |||
| EBITDA | 7.55% | 140.93% | |||
| EPS Basic | 45.77% | 83.66% | |||
| Normalized Basic EPS | -28.02% | 124.11% | |||
| EPS Diluted | 45.77% | 83.66% | |||
| Normalized Diluted EPS | -28.02% | 124.11% | |||
| Average Basic Shares Outstanding | 0.13% | 52.13% | |||
| Average Diluted Shares Outstanding | 0.13% | 52.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||